Trastuzumab Has Radically Improved Prognosis for HER2+ Breast
trastuzumab Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short
Trastuzumab works by binding to HER2, a protein involved in cell growth found in large amounts on some cancer cells This binding blocks the trastuzumab The results of this trial indicate that trastuzumab is active as a single agent and produces durable objective responses in women with HER2-overexpressing
trastuzumab Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short
trastuzumab Trastuzumab works by binding to HER2, a protein involved in cell growth found in large amounts on some cancer cells This binding blocks the
The results of this trial indicate that trastuzumab is active as a single agent and produces durable objective responses in women with HER2-overexpressing